Paul Shinn
Overview
Explore the profile of Paul Shinn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
11244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richard A, Tao D, LeClair C, Leister W, Tretyakov K, White 5th E, et al.
Chem Res Toxicol
. 2025 Jan;
38(1):15-41.
PMID: 39829241
The analytical quality of compounds subjected to high-throughput screening (HTS) impacts accurate interpretation of assay results, with poor quality samples potentially leading to false negatives or positives. The Tox21 "10K"...
2.
Senatorov I, Bowman J, Jansson K, Alilin A, Capaldo B, Lake R, et al.
Cell Rep Med
. 2024 Dec;
5(12):101868.
PMID: 39657662
Metastatic castrate-resistant prostate cancer (mCRPC) is a genetically and phenotypically heterogeneous cancer where advancements are needed in biomarker discovery and targeted therapy. A critical and often effective component of treatment...
3.
Ceribelli M, Tosto F, Zhang X, Melani C, Roschewski M, Beck E, et al.
Proc Natl Acad Sci U S A
. 2024 Nov;
121(49):e2413372121.
PMID: 39585996
Clinical trials in cancer are ideally built on a foundation of sound mechanistic rationale and well-validated drug activity in relevant disease models. The screening of approved and investigational drugs in...
4.
Hu X, Shinn P, Itkin Z, Ye L, Zhang Y, Shen M, et al.
ACS Pharmacol Transl Sci
. 2024 Aug;
7(8):2391-2400.
PMID: 39144561
As part of the NIH Helping to End Addiction Long-term (HEAL) Initiative, the National Center for Advancing Translational Sciences is dedicated to the development of new pharmacological tools and investigational...
5.
Wu J, Cheuk A, Isanogle K, Robinson C, Zhang X, Ceribelli M, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627061
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Despite decades of clinical trials, the overall survival rate for patients with relapsed and metastatic disease remains below 30%, underscoring...
6.
Lynch C, Sakamuru S, Ooka M, Huang R, Klumpp-Thomas C, Shinn P, et al.
Annu Rev Pharmacol Toxicol
. 2023 Jul;
64:191-209.
PMID: 37506331
Traditionally, chemical toxicity is determined by in vivo animal studies, which are low throughput, expensive, and sometimes fail to predict compound toxicity in humans. Due to the increasing number of...
7.
Peat T, Gaikwad S, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S, et al.
Cancer Lett
. 2023 Jun;
568:216284.
PMID: 37356470
Drug resistance and disease progression are common in multiple myeloma (MM) patients, underscoring the need for new therapeutic combinations. A high-throughput drug screen in 47 MM cell lines and in...
8.
Yasgar A, Bougie D, Eastman R, Huang R, Itkin M, Kouznetsova J, et al.
ACS Pharmacol Transl Sci
. 2023 May;
6(5):683-701.
PMID: 37200814
Dietary supplements and natural products are often marketed as safe and effective alternatives to conventional drugs, but their safety and efficacy are not well regulated. To address the lack of...
9.
Reinhold W, Wilson K, Elloumi F, Bradwell K, Ceribelli M, Varma S, et al.
Cancer Res
. 2023 May;
83(12):1941-1952.
PMID: 37140427
Significance: CellMinerCDB: NCATS provides activity information for 2,675 drugs in 183 cancer cell lines and analysis tools to facilitate pharmacogenomic research and to identify determinants of response.
10.
Wang Y, Michael S, Yang S, Huang R, Cruz-Gutierrez K, Zhang Y, et al.
J Chem Inf Model
. 2022 Jun;
62(11):2659-2669.
PMID: 35653613
To deliver more therapeutics to more patients more quickly and economically is the ultimate goal of pharmaceutical researchers. The advent and rapid development of artificial intelligence (AI), in combination with...